{"id":"W2892222821","doi":"10.1200/jco.2017.35.15_suppl.tps8055","title":"A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Lenalidomide; Clinical endpoint; Internal medicine; Regimen; Dexamethasone; Population; Multiple myeloma; Cohort; Oncology; Phases of clinical research; Surgery; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001278972,0.00179313,0.001857733,0.0004034102,0.0004324008,0.001136275,0.001064323,0.001301121,0.00550684],"category_scores_gemma":[0.0009416299,0.0008275664,0.001183571,0.0003968289,0.000890373,0.00107518,0.0004326111,0.003926975,0.001093286],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001217995,"about_ca_system_score_gemma":0.001897066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001334658,"about_ca_topic_score_gemma":0.004094862,"domain_scores_codex":[0.9996684,0.0001438035,0.00001425531,0.00007188881,0.00003382096,0.00006776942],"domain_scores_gemma":[0.9994447,0.00006553679,0.00009776228,0.00004014276,0.00003451192,0.0003172623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7598024,0.1369463,0.004656886,0.0006943906,0.0008752325,0.0002580917,0.0003698532,0.001740209,0.03421175,0.0002826625,0.003835887,0.05632636],"study_design_scores_gemma":[0.6238112,0.3640755,0.005718987,0.0000248456,0.0003373819,0.0002155822,0.00007609776,0.0008123862,0.002188258,0.000202731,0.002511613,0.00002541535],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886447,0.00125477,0.0005147901,0.0006703563,0.0001627443,0.005257634,0.001574761,0.0001054146,0.001814773],"genre_scores_gemma":[0.9802282,0.001838423,0.002935827,0.001443416,0.0002433046,0.006096044,0.002446718,0.00004916962,0.004718873],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00550684,"threshold_uncertainty_score":0.01842225,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.136880622330797,"score_gpt":0.4809013942419234,"score_spread":0.3440207719111263,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}